Top Industry Leaders in the Adrenocortical Carcinoma Treatment Market
Latest Adrenocortical Carcinoma Treatment Companies Updates:
Jan 2024
PharmaMar (Spain) Presented positive Phase 2 data demonstrating the efficacy and safety of their novel oral drug, lurbinectedin, in treating advanced ACC.Initiated Phase 3 clinical trials evaluating lurbinectedin in combination with other therapies for patients with unresectable ACC.
Eisai Co.,Received FDA Fast Track designation for their oral small molecule drug, lenvatinib, for treating inoperable ACC patients with specific genetic mutations.Partnered with leading cancer centers to conduct clinical trials investigating lenvatinib in combination with immunotherapy for treating ACC.
Shanghai Jiao Tong University School of Medicine (China) Conducted preclinical research identifying potential new therapeutic targets for ACC treatment based on gene expression analysis.Collaborated with international research teams to accelerate the development of novel therapies for ACC.
The Adrenocortical Carcinoma Foundation (ACF) (US) Launched a new patient-centered clinical trial registry specifically focused on ACC research and treatment advancements.Advocated for increased funding for ACC research and improved access to clinical trials for ACC patients.
National Cancer Institute (NCI) (US) Funded new research projects investigating the use of immunotherapy and targeted therapies in combination for treating ACC patients with specific genetic variants.Continued supporting clinical trials and collaborative research efforts aimed at improving ACC treatment outcomes.
List of Adrenocortical Carcinoma Treatment Key companies in the market
- Arqule, Pfizer Ltd.
- EnGeneIC Ltd
- Exelixis, Inc.
- Millendo Therapeutics, Inc.
- Merck & Co.
- Orphagen Pharmaceuticals, Inc.
- HRA Pharma
- Bristol-Myers Squibb Company
- General Electric Company
- WG Critical Care
- Mylan N.V.
